This site is intended only for healthcare professionals resident in the Republic of Ireland
Menu
Close
Menu
Close
Adverse reaction | Patients, % |
Infections and infestations | |
Infection | 48 |
Blood and lymphatic system disorder | |
Febrile neutropenia | 26 |
Neutropenia | 49 |
Thrombocytopenia | 51 |
Leukopenia | 35 |
Lymphopenia | 18 |
Anemia | 36 |
Metabolism and nutrition disorders | |
Decreased appetite | 12 |
Nervous system disorders | |
Headache | 28 |
Vascular disorders | |
Haemorrhage | 33 |
Gastrointestinal disorders | |
Nausea | 31 |
Abdominal pain | 23 |
Diarrhoea | 17 |
Constipation | 17 |
Vomiting | 15 |
Stomatitis | 13 |
Hepatobiliary disorders | |
Hyperbilirubinemia | 21 |
Increased transaminases | 26 |
Increased GGT | 21 |
General disorders and administration site conditions | |
Fatigue | 35 |
Pyrexia | 32 |
Chills | 11 |
Investigations | |
ALP increased | 13 |
Injury, poisoning and procedural complications | |
Infusion related reactions | 10 |
Please click here to view the importance of transplant and VOD mitigation with BESPONSA in patients with R/R B-Cell ALL
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
I accept and agree to the terms of use.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023